Targeted therapy in the era of immunotherapy
Report from the Canadian Melanoma Conference
To view the complete article click
here (pdf format)
At the Canadian Melanoma Conference, Dr. McArthur discussed the prospects of achieving long-term disease control in melanoma through a better understanding of the adaptation that occurs following administration of targeted therapies.
The development of resistance is the major clinical dilemma in targeted therapies. The problem in targeted therapy, well illustrated in the trial of cobimetinib vs placebo in combination with vemurafenib, is that, although the addition of a MEK inhibitor to a BRAF inhibitor improves progression-free survival (PFS) quite substantially, the curve continues an apparently inevitable descent towards progression and therefore resistance, except in certain subsets of patients.